DHFR and metastatic prostate carcinoma: The eight genes where higher expression was associated with worse prognosis (CYC, CYP51A1, DHFR, EBP, KIF15, PPM1D, SQLE, and UMPS) represent potential additional therapeutic targets in metastatic prostate cancer.